Part of a comprehensive low dose program, Veo is model-based iterative reconstruction (MBIR) technology that delivers imaging under 1 mSv with profound clarity. ASiR technology allows physicians to achieve ALARA (as low as reasonably achievable) dose levels without necessarily trading off clear images. Dose Check, a dose monitoring and reporting service, provides data to optimize protocols and track dose history at a patient level.

For more information: www.gehealthcare.com


Related Content

News | X-Ray

April 14, 2026 — KA Imaging is seeing continued adoption of its X-ray technology across new regions, with recent ...

Time April 15, 2026
arrow
News | Ultrasound Imaging

April 9, 2026 — GE HealthCare has announced a digital integration between the GE HealthCare bkActiv intraoperative ...

Time April 09, 2026
arrow
News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News | Teleradiology

April 1, 2026 — Premier Radiology Services has acquired Global Imaging Solutions (GLOBIS), a leading teleradiology group ...

Time April 03, 2026
arrow
News | Digital Pathology

March 29, 2026 — Leica Microsystems has introduced the Viventis SCAPE light sheet microscope. Viventis SCAPE enables ...

Time April 01, 2026
arrow
News | Radiology Business

March 31, 2026 — Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, has has ...

Time March 31, 2026
arrow
News | Radiology Imaging

March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...

Time March 30, 2026
arrow
News | Cardiac Imaging

March 28, 2026 — When Ashley Perlow felt a sharp pain shoot across her chest and into both wrists, she didn't think it ...

Time March 30, 2026
arrow
News | Digital Pathology

March 11, 2026 — Royal Philips has announced the expansion of its digital pathology portfolio with new cloud-enabled ...

Time March 26, 2026
arrow
News | FDA

March 24, 2026 — MARS Bioimaging, a New Zealand–headquartered medical device company, has received U.S. Food and Drug ...

Time March 25, 2026
arrow
Subscribe Now